The hottest Drug Approval Substack posts right now

The FDA is acting inconsistently and retroactively on approvals, and that behavior is chilling investment and innovation in vaccines and other drug development.
Clinical trials and oversight are inefficient and expensive—practices like 100% source data verification and rigid IRB processes waste resources and slow progress, so risk-based monitoring, standardized trial infrastructure, and more flexible accredited reviews could help.
Medical and market developments are moving care forward—AI can improve cancer screening, GLP-1 competition is driving down prices, and simple habits like daily walking give big health benefits—but regulatory and cultural barriers risk limiting their impact.

A senior FDA medical official who publicly challenged certain mRNA vaccine makers is leaving their post amid intense pressure. Shares of the companies he criticized jumped after the announcement.
Powerful industry and institutional forces pushed back on criticism and can derail internal reformers. That shows it’s very hard to change drug regulation from inside the current system.
The market rewarded the outcome, signaling that investors favor moves that help pharmaceutical companies. This dynamic undermines confidence in regulatory independence and efforts to hold companies accountable.

Regulators should insist on solid, placebo-controlled evidence that a treatment actually works and is safe before approving it, because without that any risk may be too much.
Drug companies and their investors often push for lower approval standards to make big profits, using weak comparisons or non-placebo studies to claim benefits.
Politics and media hype can pressure regulators to relax standards, which increases the chance that unproven, risky treatments reach patients and cause harm.

The FDA’s current review process now favors big pharmaceutical incumbents and stifles small innovators, pushing startups to sell early or move their development offshore.
Regulatory workarounds like Fast Track, Priority Review Vouchers, and Emergency Use Authorization were meant to help patients but have been captured and repurposed as shortcuts that benefit large companies more than public health.
Real reform should refocus approval on patient-centered, clinically meaningful benefits and give agency leaders and managers flexibility to adapt to modern science and take measured risks.

FDA approvals for Pfizer drugs may not have enough safety and effectiveness data. This raises concerns about the reliability of the drugs available to the public.
There is a pattern of FDA regulators moving to jobs at pharmaceutical companies after approving their products. This can create a conflict of interest and lead to questions about transparency.
The system seems designed to favor big pharmaceutical companies rather than prioritize patient safety and well-being. This indicates a troubling relationship between regulators and the companies they oversee.

Get a weekly roundup of the best Substack posts, by hacker news affinity:

Many drugs have been approved by the FDA without solid proof that they actually work. This means patients might be taking medication that doesn't help them at all.
The FDA's approval process has become too focused on getting drugs to market quickly rather than ensuring they are genuinely safe and effective. This can lead to harmful or ineffective treatments being available for long periods.
Many doctors and patients misunderstand what FDA approval really means. Just because a drug is approved doesn’t mean it has clear benefits or is safe to use.